Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Eye game could replace clinic visits for diabetics

NCT ID NCT07386613

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether people with diabetes can use a smartphone game to monitor their vision at home, instead of always going to the clinic. 55 participants at high risk for diabetic retinopathy played vision games on their phones for 6 months. The goal was to see if people would stick with the app and if it could catch early signs of eye disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

55 people

The number who actually took part.

Started

Sep 2023

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with type 1 or type 2 diabetes with either no diabetic retinopathy (R0) or early background changes (R1)

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Study 1: * The 55 participants with Type 1 or Type 2 diabetes must also be a gestational, or dialysis DR patient. * Aged 18-70. * All participants should have access to one of the following devices on a daily basis: iPhone (X, XS, XR, 11, 11 Pro, 11 Pro Max, SE 2020, 12, 12 Pro, 12 Pro Max, 12 mini); iPad (Pro 11-inch 2nd generation, Pro 12.9-inch 4th generation); Samsung Galaxy S8, S9, S10, A20e or A40; Samsung Galaxy Tab S3; Honor 10 Lite; Motorola G6 or G7 Power or Pixel 3a. * All participants should also have the ability to read and understand in English and be able to give informed consent. * All participants should also be able to tap the screen of a digital device. * All gestational and dialysis participants should be willing to undergo handheld retinal imaging, no pupil dilation is required. * Be willing to use the app from home for up to 6 months in between the participant's regular clinic visits. Study 2: * The 35 participants with type 1 or type 2 diabetes should have R0 no retinopathy or R1 background changes (this is stated on the letter they receive from the Diabetic Retinal Screening service). * Participants must already have a diabetic screening letter dated within 3 months and use a continuous glucose monitor and be willing to share the data from their monitor with the study team. They must also be willing to allow the research team access to their most recent OCT scans which will be accessed by Prof Tunde Peto. * All participants should have access to one of the following devices on a daily basis: iPhone (X, XS, XR, 11, 11 Pro, 11 Pro Max, SE 2020, 12, 12 Pro, 12 Pro Max, 12 mini); iPad (Pro 11-inch 2nd generation, Pro 12.9-inch 4th generation); Samsung Galaxy S8, S9, S10, A20e or A40; Samsung Galaxy Tab S3; Honor 10 Lite; Motorola G6 or G7 Power or Pixel 3a. * All participants should also have the ability to read and understand in English and be able to give informed consent. * All participants should also be able to tap the screen of a digital device Exclusion Criteria: Study 1 and 2: * The presence of another ocular disease that impacts vision such as age-related macular degeneration, glaucoma, or active uveitis. * Participants who are unable to tap a screen. * Serious life-threatening conditions that would preclude attendance in the longitudinal part of the study. * Neurological conditions that can impair vision * Any physical limitation that would make the participant unable to attend clinic visits (e.g., patients with arthritis or neck problems who may be unable to sit for a prolonged period of time).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes (DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Belfast Health and Social Care Trust, Belfast City Hospital

    Belfast, Belfast City, BT97AB, United Kingdom

  • Northern Health and Social Care Trust, Antrim Hospital

    Antrim, County Antrim, BT412RL, United Kingdom

  • Southern Health and Social Care Trust, Craigavon Hospital

    Craigavon, County Armagh, BT63 5QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.